WO2001070732A1 - Derives pyrazoline ou tetrahydropyridazine et utilisation medicinale de ceux-ci - Google Patents
Derives pyrazoline ou tetrahydropyridazine et utilisation medicinale de ceux-ci Download PDFInfo
- Publication number
- WO2001070732A1 WO2001070732A1 PCT/JP2001/002169 JP0102169W WO0170732A1 WO 2001070732 A1 WO2001070732 A1 WO 2001070732A1 JP 0102169 W JP0102169 W JP 0102169W WO 0170732 A1 WO0170732 A1 WO 0170732A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- carbon atoms
- dihydro
- phenyl
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the present invention relates to a novel 3′-phenyl_2-biazoline derivative and a 3-phenylenedihydrohydropyridazine derivative or a pharmaceutically acceptable salt thereof. More specifically, as a drug containing the compound and having an activity of activating a glutamate transporter, cerebral ischemic injury (cerebral infarction, cerebral edema) due to glutamate toxicity, head injury, glaucoma, retinopathy, epilepsy The present invention relates to a drug that is effective in treating and / or preventing amyotrophic lateral sclerosis (ALS). Background technology
- Glutamate is a major excitatory neurotransmitter in the central nervous system and is deeply involved in neuropathy caused by cerebral ischemia. It has been reported that daltamate is excessively effluxed by ischemia in experimental animals, and that glutamate efflux is sustainedly increased in brain tissue of patients with cerebral ischemic injury. (B. Me 1 dr urn: Trends. Pharmaco 1. Sc i. 1990, 11, 379-387) Therefore, by controlling excessive glutamate efflux induced during ischemia, cells It can be expected to protect brain tissue from death.
- Glutamic acid excessively leaked into the synaptic cleft is maintained in equilibrium by being taken up by neuronal cells or daltamate transporter present in the last mouth site.
- five transporters (GLT-1, GLAST, EAAC K ⁇ 4 and ⁇ 5) have been cloned as sodium-dependent glutamate transporters, and their functions have been elucidated in recent years.
- Glutamate transporters are activated when extracellular glutamate levels increase during ischemic injury and are thought to play an important role in protecting neurons from glutamate toxicity.
- degeneration of the glutamate transporter may be associated with amyotrophic lateral sclerosis (ALS).
- ALS amyotrophic lateral sclerosis
- An object of the present invention is to have a glutamate transporter activating action, cerebral ischemic injury (cerebral infarction, cerebral edema) caused by glutamate toxicity, sequelae of cerebral ischemic injury, head trauma, glaucoma, retina
- An object of the present invention is to provide a compound useful as a prophylactic and / or therapeutic agent for diseases, epilepsy and amyotrophic lateral sclerosis (ALS), and a pharmaceutical composition containing the compound.
- cerebral ischemic injury Cerebral infarction, cerebral edema
- ALS amyotrophic lateral sclerosis
- the present inventors have conducted intensive studies to solve the above-mentioned problems, and found that a 3-phenyl X-biru 2-birazolin derivative and a 3-phenyl-tetrahydropyridazine derivative strongly activated the dalluminic acid transporter.
- the present invention has been found to have an effect, and the present invention has been completed.
- the compound according to the present invention has the following formula (1):
- X guidesX 2 , X 3 , X 4 , and X 5 are the same or different and are each a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a trifluoromethyl group, a halogen atom, a nitro group, a carbon atom of 1 Alkoxy group having up to 6 carbon atoms, alkylthio group having 1 to 6 carbon atoms, alkyl sulfone having 1 to 6 carbon atoms A quinyl group or an alkylsulfonyl group having 1 to 6 carbon atoms.
- Y represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, and when X 5 is an alkyloxy group, an alkylthio group, an alkylsulfinyl group, an alkylsulfonyl group, or an alkyl group, X 5 and Y are combined to form 6 or It may form a 7-membered ring.
- Q represents a methylene group or an ethylene group.
- Ar is the following formula:
- R in Rn represents an alkyl group having 1 to 6 carbon atoms, a halogen atom, n represents an integer of 0 to 4, and Rn represents that R is n.
- the compound of the above formula (1) includes a 3-phenyl-2-pyrazoline derivative and a 3-phenyltetrahydropyridazine derivative. Further, a pharmacologically acceptable salt of the compound of the formula (1) is also included in the present invention.
- Preferred embodiments of the compound of the formula (1) according to the present invention include the following compounds.
- X 5 is an oxygen atom
- Y is a methylene group
- 5 and ⁇ combine to form a ring structure
- Ar is a 3-pyridyl group.
- the method for producing the compound of the above formula (1) according to the present invention comprises:
- L represents a hydroxyl group or a leaving group which can be easily displaced by a nucleophilic reagent
- Ar has the same meaning as in the case of the formula (1)
- the pharmaceutical composition according to the present invention comprises the compound of the above formula (1) or a pharmacologically acceptable salt thereof as an active ingredient.
- ischemic injury Cerebral infarction, cerebral edema
- glutamate toxicity in nerve cells sequelae of cerebral ischemic injury
- head trauma head trauma
- glaucoma head trauma
- retinopathy retinopathy
- epilepsy a pharmaceutical preparation for treatment and / or prevention of amyotrophic lateral sclerosis (ALS).
- ALS amyotrophic lateral sclerosis
- the alkyl group having 1 to 6 carbon atoms means a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms, such as methyl group, ethyl group, n-propyl group, n-butyl group, n- Pentyl group, n-hexyl group, isopropyl group, cyclopropyl group, 2-methylpropyl group, 1-methylpropyl group, t-butyl group, cyclobutyl group, cyclopentyl group, 3-methylbutyl group, 2-methylbutyl group, 1 -Methylbutyl group, 1,1-dimethylpropyl group, 1,2-dimethylpropyl group, 2,2-dimethylpropyl group, cyclohexyl group, 4-methylpentyl group, 3-methylpentyl group, 2-methylpentyl group , 1-methylpentyl, 1,2,2-trimethylpropyl, 1,1,2-trimethylpropyloxy
- halogen atom examples include an iodine atom, a bromine atom, a chlorine atom, and a fluorine atom.
- An alkyloxy group having 1 to 6 carbon atoms means a linear, branched or cyclic alkyloxy group having 1 to 6 carbon atoms, such as methoxy, ethoxy, n-propyloxy, n-butyloxy, n- Examples thereof include a pentyloxy group, an n-hexyloxy group, an isopropyloxy group, a t-butyloxy group, a cyclopropyloxy group, a cyclobutyloxy group, a cyclopentyloxy group, a cyclohexyloxy group, and the like.
- the alkylthio group having 1 to 6 carbon atoms means a linear, branched or cyclic alkylthio group having 1 to 6 carbon atoms, such as methylthio group, ethylthio group, n-propylthio group, n-butylthio group, and n? Groups such as methylthio, n-hexylthio, isopropylthio, t-butylthio, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio, and the like.
- alkylsulfinyl group having 1 to 6 carbon atoms means a linear, branched or cyclic alkylsulfinyl group having 1 to 6 carbon atoms, such as a methylsulfinyl group and ethylsulfinyl group.
- n-propylsulfinyl group n-butylsulfinyl group, n-pentylsulfinyl group, n-hexylsulfinyl group, isopropylsulfinyl group, t-butylsulfinyl group, cyclopropylsulfinyl group, cyclobutylsulfinyl group, Examples thereof include a cyclopentylsulfinyl group and a cyclohexylsulfinyl group.
- An alkylsulfonyl group having 1 to 6 carbon atoms means a linear, branched or cyclic alkylsulfonyl group having 1 to 6 carbon atoms, such as a methylsulfonyl group, an ethylsulfonyl group, and an n-propylsulfonyl group.
- N-butylsulfonyl N-butylsulfonyl, n-pentylsulfonyl, n-hexylsulfonyl, isopropylsulfonyl, t_butylsulfonyl, cyclopropylsulfonyl, cyclobutylsulfonyl, cyclopentylsulfonyl, cyclohexylsulfonyl And the like.
- the alkyl group having 1 to 4 carbon atoms of Y represents a linear, branched or cyclic alkyl group having 1 to 4 carbon atoms, such as a methyl group, an ethyl group, and an n-propyl group. , N-butyl, isopropyl, cyclopropyl, t_butyl, cyclobutyl, etc.
- the alkyl group having 1 to 6 carbon atoms of the substituent Rn represents a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms, for example, a methyl group, Ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, isopropyl, cyclopropyl, t-butyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
- the halogen atom include an iodine atom, a bromine atom, a chlorine atom, and a fluorine atom.
- any of the optical isomers of R configuration and S configuration with respect to these asymmetric carbons is included in the present invention. .
- the compound of the formula (1) can be converted into a pharmacologically acceptable salt, if necessary, for example, an inorganic acid such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid or formic acid, acetic acid, fumaric acid, Examples thereof include salts with organic acids such as citric acid, maleic acid, oxalic acid, malic acid, tartaric acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid.
- an inorganic acid such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid or formic acid
- acetic acid fumaric acid
- organic acids such as citric acid, maleic acid, oxalic acid, malic acid, tartaric acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid.
- the proportions of the formulas (2) and (3) are no particular restrictions on the proportions of the formulas (2) and (3), but usually the molar ratio of the former to the latter is 20: 1 to 1:20, preferably 1: 1 to 10: 1. is there.
- the compound obtained by this reaction can be further purified by a usual method such as recrystallization or silica gel column chromatography.
- a condensing agent can be used in the reaction.
- Suitable solvents or dispersing agents used in this reaction include, for example, benzene, toluene, xylene, 1,4-dioxane, dimethylformamide (hereinafter referred to as DMF), tetrahydrofuran (hereinafter referred to as DMF). , THF), ethyl ether, 1.2-dimethoxetane, dimethyl sulfoxide (hereinafter referred to as DMSO), chloroform, dichloromethane, 1,2-dichloroethane, and the like.
- condensing agent usable for the reaction examples include 1, 1'-carbonyldiimidazo (HAStaab: Angew.Chem.Int.Ed.Engl., L, 35367, (1962)), dicyclohexylcarposimid (hereinafter referred to as DCC), 1-ethyl-3- (3-dimethylaminopropyl) ) Carposimid, diphenylphosphoryl azide and the like.
- This reaction is carried out at a temperature from room temperature to a temperature not higher than the reflux temperature of the reaction mixture, and can be obtained, for example, by heating to -10 to 150 ° C, preferably room temperature to 100 ° C.
- the reaction time is about 1 to 48 hours, depending on the conditions.
- a carboxylic acid chloride can be synthesized from a carboxylic acid using a chlorinating agent such as thionyl chloride, oxalyl chloride, and phosphorus pentachloride.
- the acid anhydride can be synthesized from a carboxylic acid using a monoalkyl carbonate such as ethyl ethyl carbonate and a base such as triethylamine.
- Suitable solvents or dispersants used for the reaction of the 3-carboxylic acid derivative with the 3-phenyl-2-biazoline derivative and the 3-phenyltetrahydropyridazine derivative include methylethyl ketone, 1,4-dioxane, DMF, THF, ethyl ether, 1,2-dimethoxetane, dimethyl sulfoxide, benzene, xylene, toluene, chloroform, dichloromethan, 1,2-dichloroethane, pyridine, etc., and sometimes methanol, ethanol, isopropanol Alcohols such as can be used.
- the reaction between the 3-substituted phenyl-2-birazolin derivative and the 3-phenyltetrahydropyridazine derivative and the activated carboxylic acid is carried out at a temperature from room temperature to the reflux temperature of the reaction mixture. It is obtained by heating to ⁇ 150 ° C, preferably 0-100 ° C.
- the reaction time is about 1 to 48 hours, depending on the conditions.
- Bases that accelerate this reaction include, for example, organic salts such as pyridine, dimethylaminoviridine, triethylamine and diisopropylethylamine.
- inorganic bases such as sodium carbonate, sodium carbonate, sodium hydroxide, and sodium hydroxide.
- 3-phenyl-1-pyrazoline derivative and the 3-phenyl-1-tetrahydropyridazine derivative of the formula (2) can be synthesized according to the following known method.
- FJ Mc EV 0 y 3-phenyl synthesized according to J. Med. Chem., 17, 281-286 (1974): cenyl_1,4,5,6-tetrahydropyridazin-1-one According to J. Aubagnac: Bull. Chem. Soc. Fr. 2859-2868 (1972), it is possible to synthesize 3-phenyl-1,4,5,6-tetrahydropyridazine.
- CE Maxwe 11 iS-Dialkylaminopropiophenone derivative synthesized from acetofxnon derivative according to the method described in Org. Synth, col.
- the compound can be converted to a 3- (2-xyl) birubazoline derivative by the method described in Journey 1 of the General Chemistry of USSR, 27, 1155-1158 (1957).
- the compounds included in the formula (1) of the present invention include, for example, the following specific compounds: The present invention is not limited to these compounds.
- Formulation can be performed by a known method.
- various forms can be selected according to the purpose of treatment, and representative examples thereof include solid preparations, liquid preparations, and other suppositories. More specifically, the following various preparations are available.
- various carriers well known in the art can be widely used as carriers.
- carriers include lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, microcrystalline cellulose, excipients such as caic acid, water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin Binders such as solution, shellac solution, methylcellulose solution, hydroxypropylcellulose solution, polyvinylpyrrolidone solution, carboxymethylcellulose solution, dry starch, sodium alginate, powdered agar, sodium hydrogencarbonate, calcium carbonate, polyoxyethylene sorbitan fat Disintegrating agents such as fatty acid esters, sodium lauryl sulfate, glyceride stearic acid, starch, lactose, disintegrating inhibitors such as sucrose, stearic acid, cocoa butter, hydrogenated oil, quaternary ammonium base, Absorption enhancers such as sodium uryl sulfate; humec
- tablets in the case of tablets, they can be made into tablets coated with a usual coating as required, for example, sugar-coated tablets, gelatin-coated tablets, enteric-coated tablets, film-coated tablets or two-layer tablets or multilayer tablets.
- a wide variety of carriers conventionally known in this field can be used.
- carriers include excipients such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oils, kaolin, talc, binders such as gum arabic, tragacanth, gelatin, carmelose calcium, agar, etc. And the like.
- Forceps are usually prepared by mixing the active ingredient compound with the various carriers exemplified above and filling the mixture into hard gelatin capsules, soft capsules and the like according to a conventional method.
- a diluent generally used in this field for example, water, ethanol , Macrogol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters, cottonseed oil, corn oil, laccase oil, olive oil, and the like.
- water is added to the compound of the present invention, and a suspension of an aqueous solution in the presence of a suitable surfactant, and an interface of polyoxyethylene hydrogenated castor oil (HCO-60), polysorbate 80, polyethylene dalicol, etc. It can be prepared as an emulsion using an activator.
- salt, glucose or glycerin may be contained in the pharmaceutical preparation, and ordinary solubilizing agents, buffers, soothing agents and the like may be added.
- conventionally known carriers can be widely used.
- examples include polyethylene glycol, cocoa butter, higher alcohols, higher alcohol esters, gelatin, semi-synthetic glycerides, and the like.
- a coloring agent e.g., a preservative, a flavor, a flavoring agent, a sweetening agent, and other pharmaceuticals can be included in the pharmaceutical preparation.
- the administration method of these pharmaceutical preparations of the present invention is not particularly limited, and the pharmaceutical preparations are administered according to various preparation forms, age, sex and other conditions of patients, and the degree of disease.
- tablets, pills, solutions, suspensions, emulsions, powders, granules, syrups and capsules are orally administered.
- they are administered intravenously, alone or in admixture with normal replenishers such as glucose and amino acids, and if necessary intramuscularly, subcutaneously or intraperitoneally.
- Suppositories are administered rectally.
- the dosage of these pharmaceutical preparations of the present invention is appropriately selected depending on the usage, the age of the patient, gender and other conditions, and the degree of the disease.In general, the amount of the active ingredient compound is 0.001 to l, 000 mg per day per adult per day. It is good to be about. It is preferable that the active ingredient compound is contained in the dosage unit form in the range of about 0.001 to 1,000 mg.
- Production Reference Examples, Examples, Formulation Examples, and Test Examples of the present invention will be described, but the present invention is not limited thereto.
- Example 1 Starting from 3-phenyl-1,4,5,6-tetrahydropyridazine (2.9 g) and using 2-birazinoyl chloride in place of nicotinic acid chloride / hydrochloride, the procedure of Example 1 was repeated. By the same operation, 1.5 g of the title compound was obtained.
- Example 3 1-Nicotinyl 3-phenyl-1-biazoline (0.1 g) synthesized in Example 3 was dissolved in ethanol (5 ml), and 1N hydrochloric acid ethanol (0.9 ml) was added under ice cooling. The precipitated crystals were collected by filtration, washed with ether and dried to give 0.1 g of the title compound as yellow crystals.
- Oral preparation containing 1-nicotinoyl 3-phenyl-1-birazolin methanesulfonate (Example 5) as an active ingredient 50 g of the compound of the present invention, 40 g of lactose, 45 g of corn starch and 30 g of crystalline cellulose were well mixed. This was kneaded and granulated with a solution prepared by dissolving 5 g of hydroxypropylcellulose in water, and dried at 50 ° C for 4 hours. Magnesium stearate (3 g) was added to the mixture, mixed well, and pressed at a weight of 20 mg per tablet using a tableting machine to obtain tablets.
- the GLT-1 activating effect was evaluated by a test using COS-7 cells transfected with rat GLT_1.
- GLT_ 1 expressing COS- 7 cells [] -G lut ama te containing KRH soluti on (200 ⁇ 1, fi na lc on centration 2 M) was added and the 3 H amount after 3 minutes scintillator one Chillon counter one Measured.
- the test drug 100 ⁇ was dissolved in KRH soution, and treated 1 hour before the addition of [3 ⁇ 4] -glutamate.
- the effect of drug on dalmic acid uptake was expressed as a percentage of the glutamate uptake capacity of the vehicle-treated group.
- Glutamate uptake (%) [Test drug (dpm) Z control (dpm)] xlOO This test was performed according to the method of Shimada et al. (Eur. J. Pharma Co., 386, 263 -270 (1999)). I went. Table 1 shows the measurement results. Table 1. Glutamate uptake promoting action
- the rat middle cerebral artery occlusion model was prepared in accordance with the method of Tamura et al. (J. Cerebral 1 Blood Flow and Me tabo 1 ism, 53-60 (1981)). That is, the left middle cerebral artery was occluded under 9% halothane anesthesia using 9 to 10-week-old male SD rats.
- the compounds of Examples 5 and 26 were used as test drugs.
- the compound of Example 5 was intravenously administered at a dose of 100181: immediately after the occlusion for 24 hours, and the compound of Example 26 was intraperitoneally administered 50 mg Z kg immediately after the occlusion and 6 hours after the occlusion.
- test compound was administered to ddY mice, and the toxicity was examined. 10 OmgZkg of the test compound was intraperitoneally administered, and toxicity was evaluated from the rat mortality 24 hours after the administration. The results are shown in Table 3.
- the compound of the present invention has a strong activating action of dalminic acid transporter in nerve cells, cerebral ischemic injury due to glutamate toxicity (cerebral infarction, cerebral edema), cerebral ischemic injury It is useful as a prophylactic and / or therapeutic agent for sequelae, head trauma, glaucoma, retinopathy, epilepsy, amyotrophic lateral sclerosis (ALS).
- dalminic acid transporter due to glutamate toxicity (cerebral infarction, cerebral edema)
- ischemic injury It is useful as a prophylactic and / or therapeutic agent for sequelae, head trauma, glaucoma, retinopathy, epilepsy, amyotrophic lateral sclerosis (ALS).
- ALS amyotrophic lateral sclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01912487A EP1270567A4 (en) | 2000-03-21 | 2001-03-19 | PYRAZOLINE DERIVATIVES OR TETRAHYDROPYRAZOLINE DERIVATIVES AND THEIR MEDICAL USE |
US10/239,311 US6831083B2 (en) | 2000-03-21 | 2001-03-19 | Pyrazoline derivative or tetrahydropyridazine derivative and medicinal use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000078980A JP2001261675A (ja) | 2000-03-21 | 2000-03-21 | ピラゾリン誘導体またはテトラヒドロピリダジン誘導体を含有する医薬 |
JP2000-78980 | 2000-03-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001070732A1 true WO2001070732A1 (fr) | 2001-09-27 |
Family
ID=18596307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/002169 WO2001070732A1 (fr) | 2000-03-21 | 2001-03-19 | Derives pyrazoline ou tetrahydropyridazine et utilisation medicinale de ceux-ci |
Country Status (4)
Country | Link |
---|---|
US (1) | US6831083B2 (ja) |
EP (1) | EP1270567A4 (ja) |
JP (1) | JP2001261675A (ja) |
WO (1) | WO2001070732A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040191803A1 (en) | 2002-11-22 | 2004-09-30 | Michela Gallagher | Target for therapy of cognitive impairment |
US8324262B2 (en) | 2005-12-20 | 2012-12-04 | The Brigham And Women's Hospital, Inc. | Tricyclic necrostatin compounds |
MX2009007050A (es) | 2006-12-29 | 2009-09-23 | Abbott Gmbh & Co Kg | Compuestos de carboxamida y su uso como inhibidores de calpaina. |
US8791114B2 (en) * | 2011-07-01 | 2014-07-29 | Merck Patent Gmbh | Dihydropyrazoles |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01226815A (ja) * | 1988-03-07 | 1989-09-11 | Mitsui Toatsu Chem Inc | ピラゾール類を主成分とする脳浮腫抑制剤 |
JPH11292764A (ja) * | 1998-04-07 | 1999-10-26 | Mitsui Chem Inc | グルタミン酸類が関与する疾患の治療および/または予防薬 |
-
2000
- 2000-03-21 JP JP2000078980A patent/JP2001261675A/ja not_active Withdrawn
-
2001
- 2001-03-19 US US10/239,311 patent/US6831083B2/en not_active Expired - Fee Related
- 2001-03-19 WO PCT/JP2001/002169 patent/WO2001070732A1/ja not_active Application Discontinuation
- 2001-03-19 EP EP01912487A patent/EP1270567A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01226815A (ja) * | 1988-03-07 | 1989-09-11 | Mitsui Toatsu Chem Inc | ピラゾール類を主成分とする脳浮腫抑制剤 |
JPH11292764A (ja) * | 1998-04-07 | 1999-10-26 | Mitsui Chem Inc | グルタミン酸類が関与する疾患の治療および/または予防薬 |
Non-Patent Citations (2)
Title |
---|
BONDAVALLI F. ET AL., FARMACO, ED. SCI., vol. 30, no. 5, 1975, pages 391 - 398, XP002978852 * |
See also references of EP1270567A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1270567A4 (en) | 2004-09-08 |
US20030149046A1 (en) | 2003-08-07 |
US6831083B2 (en) | 2004-12-14 |
JP2001261675A (ja) | 2001-09-26 |
EP1270567A1 (en) | 2003-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3545461B2 (ja) | 二環式ヘテロ環含有スルホンアミド誘導体 | |
JP4536517B2 (ja) | γ−セクレターゼ阻害剤としてのスルホンアミド、スルファメート及びスルファミド | |
TWI296625B (en) | Novel cyclic amide derivatives | |
EP3936502A1 (en) | Pyrazine derivative and application thereof in inhibiting shp2 | |
JP5800814B2 (ja) | 複素環化合物およびその用途 | |
WO2011007819A1 (ja) | ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬 | |
WO2014047427A2 (en) | Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors | |
CN105461699B (zh) | 取代的杂环化合物及其使用方法和用途 | |
CA2966250C (en) | Six-membered ring benzo derivatives as dpp-4 inhibitor and use thereof | |
WO2013078771A1 (zh) | 一种多聚(adp-核糖)聚合酶抑制剂 | |
JPH09291034A (ja) | 縮合ピリジン化合物およびその医薬としての用途 | |
JP2006508092A (ja) | γ−セクレターゼの阻害のための環状スルファミド | |
JP2008501628A (ja) | インドール誘導体およびがんの治療用途 | |
EP2799437A1 (en) | Quinoline and cinnoline compounds and use thereof | |
WO2014180182A1 (zh) | [1,2,4]三唑并[4,3-a]吡啶类衍生物,其制备方法或其在医药上的应用 | |
TW201315727A (zh) | 尿嘧啶衍生物及其醫藥用途 | |
CN106661056A (zh) | 作为酪蛋白激酶1δ/ε抑制剂的咪唑并哒嗪衍生物 | |
TW200825061A (en) | Melanin concentrating hormone receptor-1 antagonist pyridinones | |
TW201302730A (zh) | 吡唑化合物 | |
JPWO2004043936A1 (ja) | Plk阻害剤 | |
IL296413A (en) | gpr52 modulator compounds | |
WO2005051949A1 (ja) | 新規縮合イミダゾール誘導体 | |
TW201111367A (en) | Hedgehog signal inhibitor | |
CN106349228B (zh) | 取代的喹唑啉酮类化合物及其制备方法和用途 | |
WO2001070732A1 (fr) | Derives pyrazoline ou tetrahydropyridazine et utilisation medicinale de ceux-ci |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CN KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10239311 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001912487 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001912487 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001912487 Country of ref document: EP |